State Notice Laws Are Reshaping Healthcare Dealmaking

On June 11, Washington became the latest state to require healthcare buyers and sellers to notify a regulator before they close. The new law joins a growing group of state notice regimes that are quietly changing how healthcare deals get done. They lengthen timelines, expand the paperwork, and give state attorneys general a formal window to scrutinize, and sometimes slow, transactions that once cleared with little outside review.

What Washington's New Law Actually Requires

Washington's House Bill 2548, signed in late March and effective June 11, amends the state's existing health care transaction review law. The core obligation is straightforward: the parties to any transaction that produces a "material change" must submit written notice to the attorney general at least 60 days before the deal takes effect.

The reach is in how broadly the law defines a material change. The triggers now include a change in majority ownership or control of a hospital, hospital system, or provider organization; a sale or transfer of a majority of an entity's assets (including real estate sale-leaseback arrangements, where a company sells its property and leases it back); and the conversion of a nonprofit healthcare entity into a for-profit one. Parties also have to identify anyone holding a majority ownership, investment, or controlling interest, a requirement clearly aimed at the layered ownership structures common in private equity.

Filing fees scale with deal size, from $2,500 for transactions up to $1 million to as much as $25,000 for deals above $20 million. The provision that matters most for timing, though, is the standstill: if the attorney general requests additional information, the transaction cannot close until 30 days after the parties have substantially complied. That single clause turns a fixed 60-day waiting period into an open-ended one, because the clock effectively restarts whenever the regulator asks a question.

A Patchwork, Not a Single Filing

Washington is not acting alone. It is now one of roughly ten states with a healthcare transaction notice or review regime, a list that includes California, Illinois, Massachusetts, Oregon, Rhode Island, Indiana, Maine, New York, and Connecticut. Practitioners have started calling these "mini-HSR" laws, a reference to the federal Hart-Scott-Rodino Act, which requires parties to larger deals to notify the Federal Trade Commission and the Department of Justice and wait before closing.

The comparison is useful but incomplete. Federal review is a single, uniform filing with one set of rules. The state laws are the opposite. Each state runs its own process, with its own triggers, its own information demands, its own notice period, and its own authority to delay or block a deal. Notice windows alone range widely: 60 days in Washington, 90 days to California's Office of Health Care Affordability, a 90-day review in Indiana, and up to 180 days in Oregon.

For a single-state clinic, that means one filing and one timeline. For a multistate provider or a platform acquiring across state lines, it can mean several filings running at the same time, each on its own schedule, with the longest one setting the pace for the entire deal.

Why Private Equity Sits at the Center

The ownership-disclosure requirements are not incidental. Several states have written their rules specifically to surface private equity sponsors and the management services organizations (companies that own the business operations around a medical practice while leaving clinical decisions to licensed physicians) that often sit between a fund and the providers it backs. The intent is to make consolidation visible to regulators who have grown more attentive to who owns the care delivered in their states.

That attention lands on a sector that has been one of the most active in the market. Health-services deal value reached roughly $18 billion in the first quarter of 2026, and private equity accounted for much of it. In a single month earlier this year, private-equity-backed platforms rolled up more than twenty outpatient practices and close to twenty dental practices across specialties ranging from cardiology to dermatology.

That roll-up model depends on completing many small add-on acquisitions quickly and repeatably. Notice laws raise the cost and the calendar of each one, which changes the economics of a strategy built for speed. A 60-day filing is manageable on a single large deal; applied to a pipeline of small tuck-ins, it adds up.

What It Means for Buyers and Sellers

For sellers, the practical effect is a longer runway and more documentation. The notice period has to be built into the deal calendar from the start, not discovered late, and the exclusivity window granted to a buyer should reflect it. Sellers under financial pressure face the sharpest version of this problem. A notice clock that runs 60 to 180 days does not pause for a company running low on cash, which makes these laws especially consequential for distressed transactions that need to close quickly.

For buyers, and for the private equity firms building platforms, diligence now includes a regulatory-mapping step. Before signing, the buyer should know every state where the target operates and confirm which notice regimes apply, what each one triggers, and how long each one takes. Missing a required filing is not a paperwork problem; it can unwind a closing.

The deal documents will carry the rest of the weight. Expect closer negotiation over the outside date (the deadline by which a deal must close or either party can walk away), interim operating covenants that govern how the business runs during the waiting period, and the allocation of filing fees and regulatory risk between buyer and seller.

The Trend Line

The direction of travel is toward more notice, more disclosure, and longer review windows. Several new state regimes take effect this summer, and others are in the legislative pipeline. Maine, for example, has proposed requiring 180-day pre-closing notice from providers with more than $10 million in assets or revenue. The pattern reflects a broader move by states to watch healthcare consolidation and private equity ownership more closely, even as federal antitrust review stays concentrated on the largest deals.

None of this is likely to stop most healthcare transactions. What it changes is the schedule and the preparation required to get them done. The deals that move smoothly will be the ones that treated the regulatory calendar as a gating item from day one.